WO2009012275A1 - Pyridone gpr119 g protein-coupled receptor agonists - Google Patents

Pyridone gpr119 g protein-coupled receptor agonists Download PDF

Info

Publication number
WO2009012275A1
WO2009012275A1 PCT/US2008/070101 US2008070101W WO2009012275A1 WO 2009012275 A1 WO2009012275 A1 WO 2009012275A1 US 2008070101 W US2008070101 W US 2008070101W WO 2009012275 A1 WO2009012275 A1 WO 2009012275A1
Authority
WO
WIPO (PCT)
Prior art keywords
nri
cycloalkyl
aryl
alkyl
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/070101
Other languages
English (en)
French (fr)
Other versions
WO2009012275A9 (en
Inventor
Dean A. Wacker
Karen A. Rossi
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HK10109487.9A priority Critical patent/HK1143136B/en
Priority to SI200830464T priority patent/SI2170864T1/sl
Priority to NZ582664A priority patent/NZ582664A/en
Priority to BRPI0815097A priority patent/BRPI0815097A2/pt
Priority to CN200880108168A priority patent/CN101801957A/zh
Priority to DK08781867.0T priority patent/DK2170864T3/da
Priority to PL08781867T priority patent/PL2170864T3/pl
Priority to HR20110806T priority patent/HRP20110806T1/hr
Priority to EP08781867A priority patent/EP2170864B1/en
Priority to AT08781867T priority patent/ATE524460T1/de
Priority to EA201000210A priority patent/EA018709B1/ru
Priority to AU2008276055A priority patent/AU2008276055B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to CA2693439A priority patent/CA2693439A1/en
Priority to JP2010517122A priority patent/JP5318867B2/ja
Publication of WO2009012275A1 publication Critical patent/WO2009012275A1/en
Priority to ZA2010/00151A priority patent/ZA201000151B/en
Anticipated expiration legal-status Critical
Publication of WO2009012275A9 publication Critical patent/WO2009012275A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • Diabetes mellitus is a serious disease afflicting over 100 million people worldwide. In the United States, there are more than 12 million diabetics, with 600,000 new cases diagnosed each year. Diabetes mellitus is a diagnostic term for a group of disorders characterized by abnormal glucose homeostasis resulting in elevated blood sugar. There are many types of diabetes, but the two most common are Type 1 (also referred to as insulin-dependent diabetes mellitus or IDDM) and Type 2 (also referred to as non-insulin-dependent diabetes mellitus or NIDDM).
  • IDDM insulin-dependent diabetes mellitus
  • NIDDM non-insulin-dependent diabetes mellitus
  • diabetes The etiology of the different types of diabetes is not the same; however, everyone with diabetes has two things in common: overproduction of glucose by the liver and little or no ability to move glucose out of the blood into the cells where it becomes the body's primary fuel.
  • people who do not have diabetes rely on insulin, a hormone made in the pancreas, to move glucose from the blood into the cells of the body.
  • people who have diabetes either do not produce insulin or cannot efficiently use the insulin they produce; therefore, they cannot move glucose into their cells.
  • Glucose accumulates in the blood creating a condition called hyperglycemia, and over time, can cause serious health problems.
  • Diabetes is a syndrome with interrelated metabolic, vascular, and neuropathic components.
  • the metabolic syndrome generally characterized by hyperglycemia, comprises alterations in carbohydrate, fat and protein metabolism caused by absent or markedly reduced insulin secretion and/or ineffective insulin action.
  • the vascular syndrome consists of abnormalities in the blood vessels leading to cardiovascular, retinal and renal complications. Abnormalities in the peripheral and autonomic nervous systems are also part of the diabetic syndrome.
  • Diabetes has also been implicated in the development of kidney disease, eye diseases and nervous-system problems. Kidney disease, also called nephropathy, occurs when the kidney's "filter mechanism" is damaged and protein leaks into urine in excessive amounts and eventually the kidney fails. Diabetes is also a leading cause of damage to the retina at the back of the eye and increases risk of cataracts and glaucoma.
  • diabetes is associated with nerve damage, especially in the legs and feet, which interferes with the ability to sense pain and contributes to serious infections. Taken together, diabetes complications are one of the nation's leading causes of death. [0007] Many people with NIDDM have sedentary lifestyles and are obese; they weigh approximately 20% more than the recommended weight for their height and build. Furthermore, obesity is characterized by hyperinsulinemia and insulin resistance, a feature shared with NIDDM, hypertension and atherosclerosis. [0008] Obesity, which is the result of an imbalance between caloric intake and energy expenditure, is highly correlated with insulin resistance and diabetes in experimental animals and human. However, the molecular mechanisms that are involved in obesity-diabetes syndromes are not clear.
  • Type 2 diabetes results from the progressive loss of pancreatic ⁇ -cell function in the presence of insulin resistance, leading to an overall reduction in insulin output (Prentki, M. et al., "Islet failure in type 2 diabetes", J. Clin. Invest., 116: 1802-1812 (2006)).
  • ⁇ -cells are the cell type that store and release insulin in response to an elevation in plasma glucose or in response to hormonal signals from the gut following the ingestion of food.
  • Evidence suggests that in type 2 diabetics the rate of ⁇ -cell cell death (apoptosis) exceeds that of new ⁇ -cell development, yielding an overall loss in ⁇ -cell number (Butler, A.E.
  • ⁇ -cell deficit and increased ⁇ - cell apoptosis in humans with type 2 diabetes may arise from persistent elevations in plasma glucose levels (glucotoxicity) and/or plasma lipid levels (lipotoxicity).
  • G-protein coupled receptors expressed on ⁇ -cells are known to modulate the release of insulin in response to changes in plasma glucose levels (Ahren, B., "Autonomic regulation of islet hormone secretion - Implications for health and disease", Diabetologia. 43:393-410 (2003)). Those GPCRs specifically coupled to the elevation of cAMP via the G 5 alpha subunit of G-protein, have been shown to enhance glucose-stimulated insulin release from ⁇ -cells. Cyclic AMP- stimulating GPCRs on ⁇ -cells include the GLP-I, GIP, ⁇ 2-adrenergic receptors and GPRl 19.
  • GPRl 19 (e.g., human GPRl 19, GenBank® Accession No. AAP72125 and alleles thereof; e.g., mouse GPRl 19, GenBank® Accession No. AY288423 and alleles thereof) is a GPCR located at chromosome position Xp26.1 (Fredricksson, R. et al, "Seven evolutionarily conserved human rhodopsin G protein-coupled receptors lacking close relatives", FEBS Lett.. 554:381-388 (2003)). The receptor is coupled to Gs, and when stimulated, produces an elevation in cAMP in a variety of cell types including ⁇ -cell-derived insulinomas (Soga, T.
  • GPRl 19 Activation of GPRl 19, with agonist ligands such as lysophosphatidylcholine, produce a glucose dependent increase in insulin secretion from primary mouse islets and various insulinoma cell lines such as NIT- 1 and HIT-T 15 (Soga, T. et al., "Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor", Biochem. Biophys. Res. Comm.. 326:744-751 (2005); Chu, ZX. et al., "A role for ⁇ -cell-expressed GPRl 19 in glycemic control by enhancing glucose-dependent insulin release", Endocrinology. doi: 10.1210/ en.2006-1608 (2007)).
  • agonist ligands such as lysophosphatidylcholine
  • n ls n 2 , n 3 , G, Q, X, R 1 , R 2 , R 2 0 and R 21 are defined below.
  • Compounds of the present invention modulate the activity of G protein- coupled receptors.
  • compounds of the present invention modulate the activity of the GPRl 19 G protein-coupled receptor ("GPRl 19"). Consequently, the compounds of the present invention may be used in the treatment of multiple diseases or disorders associated with GPRl 19, such as diabetes and related conditions, microvascular complications associated with diabetes, the macrovascular complications associated with diabetes, cardiovascular diseases, Metabolic Syndrome and its component conditions, obesity and other maladies.
  • diseases or disorders associated with the modulation of the GPRl 19 G protein-coupled receptor that can be prevented, modulated, or treated according to the present invention include, but are not limited to, diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL, high LDL, non-cardiac ischemia, infection, cancer, vascular restenosis, pancreatitis, neurodegenerative disease, lipid disorders, cognitive impairment and dementia, bone disease, HIV protease associated lipodystrophy and glaucoma.
  • the present invention relates to a formulated product wherein the selected formulation is made by using a compound of Formula I and/or IA as the only active ingredient or by combining (a) a compound of Formula I and/or IA (using any of the compound embodiments listed herein) and (b) an additional active ingredient, for example, dipeptidyl peptidase-IV (DPP4) inhibitor (for example a member selected from saxagliptin, sitagliptin, vildagliptin and alogliptin).
  • DPP4 dipeptidyl peptidase-IV
  • the present invention provides for compounds of Formula I and IA, pharmaceutical compositions employing such compounds, and for methods of using such compounds.
  • the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of Formula I and/or IA, alone or in combination with a pharmaceutically acceptable carrier.
  • a method is provided for preventing, modulating, or treating the progression or onset of diseases or disorders associated with the activity of the GPRl 19 G protein-coupled receptor, such as defined above and hereinafter, wherein a therapeutically effective amount of a compound of Formula I and/or IA is administered to a mammalian, i.e., human, patient in need of treatment.
  • the compounds of the invention can be used alone, in combination with other compounds of the present invention, or in combination with one or more other agent(s).
  • the present invention provides a method for preventing, modulating, or treating the diseases as defined above and hereinafter, wherein a therapeutically effective amount of a combination of a compound of Formula I or IA and another compound of Formula I or IA and/or at least one other type of therapeutic agent, is administered to a mammalian, i.e., human, patient in need of treatment.
  • a mammalian i.e., human
  • Formula IA including enantiomers, diastereomers, solvates and salts thereof (particularly enantiomers, diastereomers and pharmaceutically acceptable salts thereof) having ring A and ring B, wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ; G is CH or N;
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ; Ria, Rib, Ric, Rid and Ri e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 10 , -OCF 3 , -ORn, -OH, -SH, -SRn, -S(O) 3 H, -P(O) 3 H 2 , -C(K))NR 9 R 9 , -NRi 2 Ri 2 , -S(O) 2 NR 9 R 9
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R ⁇ at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 ,
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , -
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , -
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Rioa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u,
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl 0, -NR 9 C(O)OR 8 and -NR 9 S(O 2 )R 8 , wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ; R 8 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , -
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is phenyl, pyridinyl, pyrazinyl or pyrimindinyl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e, '
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 6 is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , ,
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri la ;
  • G is CH or N
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • U 1 is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is phenyl or pyridinyl, each of which may be optionally substituted with one or more members selected from R 1 a , R 11 ,, R lc , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 10 , -OCF 3 , -ORn, -OH, -SH, -SRn, -S(O) 3 H, -P(O) 3 H 2 , -C(K))NR 9 R 9 , -NRi 2 Ri 2 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl 0, -NR 9 C(O)OR 8 and -NR 9 S(O 2 )R 8 , wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ; R 8 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , -
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2; , each of which may be optionally substituted with one or more members selected from the group consisting of R la , Rib, R 1 c , Rid and Ri 6 ;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl, wherein the heteroaryl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , -
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , -
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ; Rioa, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -OR
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri la ;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • R 14 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 0-2; n 2 is 0-2; n 3 is 1-2;
  • cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • Re at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 10 , -
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N;
  • Q is C or N
  • cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R9 a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u, Riia, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri o a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 0-2; n 2 is 0-2; n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo,
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R7, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 Rg a ;
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • X is CH or N, provided that Q and X are not both N;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 2 is aryl, heteroaryl or -C(O)ORs, wherein the aryl and heteroaryl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • Re at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORio,
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 , -OH, -SH, -SRi 4 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NRi 4 Ri 4 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)NRi 4 S(O) 2 Ri 4 , -S(O) 2 NRi 4 C(O)OR
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -OR 14 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • Ri 2 at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; and
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • Q is C or N;
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rg at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 Rg a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u,
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; and
  • R 2 o and R 21 are each independently selected from the group consisting of hydrogen, alkyl, haloalkyl, cycloalkyl, halo, -CN, -C(O)OH, -C(O)OR 10 , -OCF 3 ,
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ; G is CH or N;
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rib, Ric, Rid and Ri e ;
  • R 2 is heteroaryl which may be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R ⁇ at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 ,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , -
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , -
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ; Rioa, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -OR
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri la ;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N
  • Q is C or N;
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl 0, -NR 9 C(O)OR 8 and -NR 9 S(O 2 )R 8 , wherein the alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ; R 8 , at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , -
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • G is CH or N
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N;
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 2 is pyrimidinyl which may be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 0 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ; RiOa, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri la ;
  • ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N
  • Q is C or N
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 2 is -C(O)OR 5 ;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • G is CH or N
  • Q is C or N
  • X is CH or N, provided that Q and X are not both N; Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 0-2; n 2 is 0-2; n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • Ria, Rib, Ric, Rid and Ri e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 10 , -OCF 3 , -ORn, -OH, -SH, -SRn, -S(O) 3 H, -P(O) 3 H 2 , -C(K))NR 9 R 9 , -NRi 2 Ri 2 , -S(O) 2 NR 9 R
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 6 is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, , -C(O)OR 10 , -OCF 3 , -ORi 0 , -OH, -SH, - SRi 0 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)R 10 , -NR 9 C(O)H, -NR 9 C(O)Ri 0 , -OC(O)Ri 0 , -S(O)Ri 0 , -S(O) 2 Ri 0 , O, -NR
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 Rg a ;
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • X is CH or N, provided that Q and X are not both N;
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R9 a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u, Riia, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri o a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 20 and R 21 ; G is CH or N;
  • Q is C or N
  • X is CH
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 0-2; n 2 is 0-2; n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • Re at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 ,
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I and Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 1-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R9 a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u, Riia, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri o a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 20 and R 21 ; G is CH or N;
  • X is CH
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 0-2; n 2 is 0-2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo,
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R7, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 Rg a ;
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • ni is 0-2;
  • n 2 is 0-2;
  • n 3 is 2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R9 a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u, Riia, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri o a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 20 and R 21 ; G is CH or N;
  • X is CH
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 1; n 2 is 1;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo,
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R7, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 Rg a ;
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula I are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e ;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 4 , - OCF 3 , -ORi 4 ,
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R9 a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 ,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri u, Riia, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 14 , - OCF 3 , -ORi 4 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri o a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 20 and R 21 ; G is CH or N;
  • X is CH
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ; ni is 1; n 2 is 1;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo,
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R7, at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 Rg a ;
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rg at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ; Rioa, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)OR 14 , -OCF 3 , -OR 14 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 and -NRi 4 S(O 2 )R 8 ;
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • X is CH
  • Y is CH 2 , N(R 3 ), C(O), O, OCR 9 R 9 , S, S(O) or S(O) 2 ;
  • ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 10 , -OCF 3 , -ORn, -OH, -SH, -SRn, -S(O) 3 H, -P(O) 3 H 2 , -C(K))NR 9 R 9 , -NRi 2 Ri 2 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O)
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 6 is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , ,
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • Ri 0 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri Oa ;
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R 1 la ;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 and -NRi 4 S(O 2 )R 8 ;
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • X is CH
  • Y is O, OCR 9 R 9 , or S,; ni is 1; n 2 is 1 ;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • Re at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 ,
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S
  • R 8a is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rg at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ; Rioa, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)OR 14 , -OCF 3 , -OR 14 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 and -NRi 4 S(O 2 )R 8 ;
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • X is CH
  • Y is O, OCR 9 R 9 or S; ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is a 6-membered monocyclic aryl, a 5-membered monocyclic heteroaryl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R la , Rn,, R 1 c , Rid and R le ;
  • R 1 a , Rib, Ric, Rid and R 1 e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)OR 10 , -OCF 3 , -ORn, -OH, -SH, -SRn, -S(O) 3 H, -P(O) 3 H 2 , -C(K))NR 9 R 9 , -NRi 2 Ri 2 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O)
  • R 2 is cycloalkyl, aryl, heteroaryl, heterocyclyl, -S(O) 2 R 5 , -C(O)NR 3 R 5 , -C(O)R 5 or -C(O)OR 5 , wherein the cycloalkyl, aryl, heteroaryl and heterocyclyl may each be optionally substituted with one or more Re's;
  • R 3 is hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 6 is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , ,
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • Ri 0 is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri Oa ;
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 R 1 la ;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 and -NRi 4 S(O 2 )R 8 ;
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • compounds of Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N
  • X is CH
  • Y is O, OCR 9 R 9 or S; ni is 1; n 2 is 1 ;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R 1 a , R 11 ,, R 1 c , Rid and
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R ⁇ at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , - OCF 3 , -ORi 0 ,
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -NH 2 , -CN, -NO 2 , -C(O)OH, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -S(O) 3 H, -P(O) 3 H 2 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)NR 9 S(O) 2 R 9 , -S(O) 2 NR 9 C(O)OR 9 , -S(O) 2 NR 9 C(O)OR 9 , -S
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 2 at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • Y is O, OCR 9 R 9 or S; ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and
  • Ria, Rib, Ric, Rid and Ri e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo,
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 9 is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 2 at each occurrence, is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -CN, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -C(O)NR 9 R 9 , -NR 9 R 9 ,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rg at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ; Rioa, at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)OR 14 , -OCF 3 , -OR 14 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 ,
  • Ri 2 is independently selected from hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is CH or N;
  • X is CH
  • Y is O, OCR 9 R 9 , or S; ni is 1; n 2 is l; n 3 is 2;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R 1 a , Rn,, R 1 c , Rid and
  • Ri e Ri e ;
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R ⁇ at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, - SRi 0 ,
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl, aryl, cycloalkyl, heteroaryl and heterocyclyl, each of which may be optionally substituted with one or more R 8a 's;
  • R9 at each occurrence, is independently selected from hydrogen, alkyl, alkoxy, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 Rg a ;
  • Rg a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 ,
  • Rio at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Rio a ;
  • RiOa is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H,
  • R 11 at each occurrence, is independently selected from alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl, wherein the cycloalkyl, aryl, arylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-3 Ri la ;
  • R20 is hydrogen
  • ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • R5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 ,
  • R9 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl, and aryl, wherein the alkyl, cycloalkyl, and aryl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl, and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • Rn at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R ⁇ a ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula I are provided wherein: ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is CH or N; Q is C;
  • X is CH
  • Y is O, OCR 9 R 9 or S; ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e, '
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H, -NR 14 C(O)R 14 , -0C(O)R 14 ,-S(O)R 14 , -S(O)
  • Rn at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R ⁇ a ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; R 2 o is hydrogen; and
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is N
  • X is CH; Y is O, OCR 9 R 9 or S; ni is 1; n 2 is 1 Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and Ri e, '
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 6 at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, - SRi 0 ,
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)ORi 4 , -OCF 3 ,
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)ORi 4 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NR 14 R 14 ⁇ NR 14 S(O) 2 CF 3 , -C(O)Ri 4 , -NR 14 C(O)H,-NR 14 C(O)R 14 , -OC(O)Ri 4 , -S(O)Ri 4 , -S(O) 2 Ri 4 , -NR 14 C(O)OR 8 , -NRi 4 S(O 2 )R 8 and O;
  • Ri 0 is independently selected from alkyl, cycloalkyl, and aryl, which may each be optionally substituted with 0-3 Ri Oa ;
  • R 1 Oa is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)ORi 4 , -OCF 3 , -OR 14 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)Ri 4 , -NRi 4 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 and -NRi 4 S(O 2 )R 8 ;
  • R 11 at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R lla ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is N
  • X is CH
  • Y is O, OCR 9 R 9 or S; ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R 1 a , Rn,, R 1 c , Rid and Ri 6 ;
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R ⁇ at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, - SRi 0 ,
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • R9 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl, and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • R 11 at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R lla ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • ring A is optionally substituted with one or more R's shown as R 20 and R 21 ;
  • G is N
  • X is CH; Y is O; ni is 1; n 2 is 1 ;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rib, Ric, Rid and Ri 6 ;
  • Ria, Rib, Rid and Ri e are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, halo, -CN, -OCF 3 , -ORn, -OH, -C(O)NR 9 R 9 , -NR12R12, -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)Rn, -NR 9 C(O)H, -NR 9 C(O)Ri 0 , -OC(O)R 10 , -OC(O)NR 9 R 9 , -S(O)R 11 , -S(O) 2 Rn, -NR 9 C(O)OR 8 and -NR 9 S(O 2 )R 8 , wherein: (a) the alkenyl, alkynyl and cycloalkyl, may each be optionally substituted with one or more Re
  • R lc is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocyclyl, halo, -CN, -OCF 3 , -ORn, -OH, -SRn, -C(O)NR 9 R 9 , -NRi 2 Ri 2 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)R 11 , -NR 9 C(O)H, -NR 9 C(O)Ri 0 , -OC(O)R 10 , -OC(O)NR 9 R 9 , -S(O)Rn, -S(O) 2 Rn, -NR 9 C(O)OR 8 and -NR 9 S(O 2 )R 8 , wherein: (a) the alkenyl, alkynyl, cycloalkyl, aryl and heterocycl
  • R 6 at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, -C(O)OR 10 , -OCF 3 , -ORi 0 , -OH, -SH, - SRio,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 R 9a ;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl, and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Rio a ;
  • R 14 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • X is CH
  • Y is O; ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -CN, -C(O)OR 10 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -C(K ) )NR 9 R 9 , -NR 9 R 9 ,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)ORi 4 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)Ri 4 ,
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)ORi 4 , -OCF 3 ,
  • Ri 0 at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Ri Oa ;
  • R 1 Oa is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)ORi 4 , -OCF 3 , -OR 14 , -OH, -C(O)NR 14 R 14 ,
  • R 11 at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R lla ;
  • Rii a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 , -NR 14 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 and -NRi 4 S(O 2 )R 8 ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Ri Oa ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • compounds of Formula IA are provided wherein: ring A is optionally substituted with one or more R's shown as R 20 and R 21 ; G is N;
  • X is CH
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from R 1 a , R 11 ,, R 1 c , Rid and
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • Re at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, - SRi 0 , -C(O)NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3 , -C(O)R 10 , -NR 9 C(O)H, -NR 9 C(
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • Rn at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R ⁇ a ;
  • R 14 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 0 is hydrogen
  • R 21 is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN.
  • ring A is optionally substituted with one or more R's shown as R20 and R21; G is N; Q is C; X is CH; Y is O; ni is 1; n 2 is 1 ; n 3 is 2;
  • Ri is phenyl or a 6-membered monocyclic heteroaryl, each of which may be optionally substituted with one or more members selected from Ri a , Rn,, Ri c , Rid and
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 6 at each occurrence, is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, halo, -CN, -C(O)OR 10 , -OCF 3 , -ORi 0 , -OH, -SH, -
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • Rn at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R ⁇ a ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • R 2I is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN.
  • ring A is optionally substituted with one or more R's shown as R20 and R21;
  • G is N
  • X is CH
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -CN, -C(O)OR 10 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -C(K))NR 9 R 9 , -NR 9 R 9 ,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 , -ORi 4 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)R 14 ,
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 ,
  • Ri 0 is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Ri Oa ;
  • Rn at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R ⁇ a ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Ri o a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • R 2I is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN.
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is N
  • Q is C; X is CH;
  • Y is O; ni is 1; n 2 is 1 ; n 3 is 2;
  • R 2 is heteroaryl or -C(O)ORs, wherein the heteroaryl may be optionally substituted with one or more Re's;
  • R 5 is alkyl, alkenyl, aryl, cycloalkyl, heteroaryl or heterocyclyl, each of which may be optionally substituted with one or more Re's;
  • R 7 at each occurrence, is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -CN, -C(O)OR 10 , -OCF 3 , -ORio, -OH, -SH, -SRi 0 , -C(K ) )NR 9 R 9 , -NR 9 R 9 , -S(O) 2 NR 9 R 9 , -NR 9 S(O) 2 CF 3
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 R 9a ;
  • R 9a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)ORi 4 , -OCF 3 ,
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • RiOa is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, halo, -NH 2 , -CN, -C(O)ORi 4 , -OCF 3 , -OR 14 , -OH, -C(O)NR 14 R 14 , -NRi 4 Ri 4 , -S(O) 2 NRi 4 Ri 4 , -NRi 4 S(O) 2 CF 3 , -C(O)Ri 4 , -NRi 4 C(O)H, -NR 14 C(O)R 14 , -OC(O)R 14 , -S(O)R 14 , -S(O) 2 Ri 4 , -NRi 4 C(O)OR 8 , and -NRi 4 S(O 2 )R 8 ;
  • R 11 is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R lla ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Rio a ;
  • Ri 4 is independently selected from hydrogen, alkyl, cycloalkyl and aryl;
  • R 2 o is hydrogen
  • R 2I is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN.
  • ring A is optionally substituted with one or more R's shown as R 2 o and R 21 ;
  • G is N
  • X is CH
  • R 5 is alkyl, aryl or cycloalkyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 7 is independently selected from the group consisting of alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocyclyl, halo, -CN, -C(O)ORi 0 , -OCF 3 , -ORi 0 , -OH, -SH, -SRi 0 , -C(O)NR 9 R 9 , -NR 9 R 9 ,
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl and heterocyclyl may each be optionally substituted with 0-5 R 9a ;
  • Rg at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 Rg a ;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • R 11 at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R lla ;
  • Ri 2 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-3 Ri Oa ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; R20 is hydrogen; and
  • R 21 is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN.
  • ring A is optionally substituted with one or more R's shown as R 2 0 and R 21 ;
  • G is N
  • X is CH; Y is O; ni is 1; n 2 is 1 ; n 3 is 2;
  • R 5 is alkyl, aryl or cycloalkyl, each of which may be optionally substituted with one or more Re's;
  • alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl may each be optionally substituted with 0-5 R 9a ;
  • R 8 at each occurrence, is independently selected from the group consisting of alkyl and cycloalkyl, each of which may be optionally substituted with one or more R 8a 's;
  • R 8a is independently selected from alkyl, haloalkyl, aryl, alkenyl, alkynyl, cycloalkyl, halo, -NH 2 , -CN, -C(O)OH, -C(O)OR 14 , -OCF 3 ,
  • R 9 is independently selected from hydrogen, alkyl, cycloalkyl and aryl, wherein the alkyl, cycloalkyl and aryl may each be optionally substituted with 0-5 R 9a ;
  • Rio at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 Rio a ;
  • Rn at each occurrence, is independently selected from alkyl, cycloalkyl and aryl, which may each be optionally substituted with 0-3 R ⁇ a ;
  • Ri 4 at each occurrence, is independently selected from hydrogen, alkyl, cycloalkyl and aryl; R 2 o is hydrogen; and
  • R 2I is selected from the group consisting of hydrogen, alkyl, haloalkyl, halo and -CN.
  • One particular group of compounds is the group of embodiments of Formula I.
  • Another particular group of compounds is the group of embodiments of Formula IA (noting that for Formula IA there is no n 3 in the formula).
  • the heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl used in each occurrence may each contain 1-4 heteroatoms selected from N, O and S.
  • R 2 may be selected from -C(K))ORs, a 5-6 membered monocyclic heteroaryl having 1-3 heteroatoms selected from O and N; and an 8-10 bicyclic heteroaryl having 1-3 heteroatoms selected from O and N, wherein: i) the heteroaryls may be each be substituted with 1 or 2 of R 6 , where R 6 is selected from Ci-6 alkyl, C 1-3 haloalkyl, phenyl, C3-6 cycloalkyl, halo, -CN, -OCF3 and -OCi_ 5 alkyl, wherein the alkyl, phenyl, and cycloalkyl values for R 6 may each be optionally substituted with 0-2 R 9a where Rg a is selected from halo, C 1-3 haloalkyl, C3-6 cycloalkyl, OH, C 1-3 alkoxy and CN; and ii) R5 is selected from the group consisting of Ci_ 6 straight and
  • R5 may be selected from the group consisting of Ci-6 straight and branched chain alkyl, C 3 _ 6 cycloalkyl and phenyl wherein: i) the alkyl, phenyl, and cycloalkyl, may each be optionally substituted with 0-2 R 6 ; ii) R 6 is selected from Ci_ 6 straight and branched chain alkyl; C3_ 6 cycloalkyl; C 2 - 6 alkenyl; C 2 - 6 alkynyl; OH; phenyl; halo; Ci_ 6 haloalkyl; 5-6 membered heteroaryl having carbon atoms and 1-2 heteroatoms selected from O, S and N; 5-6 membered heterocycle having carbon atoms and 1-2 heteroatoms selected from O and N; OCF 3 ; OR 1 0 where Rio is C 1-3 alkyl or C3- 6 cycloalkyl; and SR 1 0 where Rio is Ci_3 alkyl or
  • Re may be selected from C 1 ⁇ straight and branched chain alkyl; C3-6 cycloalkyl; C 2 -6 alkenyl; C 2 -6 alkynyl; OH; phenyl; halo; C 1 ⁇ haloalkyl; 5-6 membered heteroaryl having carbon atoms and 1 -2 heteroatoms selected from O, S and N; 5-6 membered heterocycle having carbon atoms and 1-2 heteroatoms selected from O and N; OCF3; OR10 where Rio is C 1-3 alkyl or C3-6 cycloalkyl; and SR10 where

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
PCT/US2008/070101 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists Ceased WO2009012275A1 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SI200830464T SI2170864T1 (sl) 2007-07-17 2008-07-16 Piridon gpr119g proteinsko povezani receptorski antagonisti
NZ582664A NZ582664A (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists
BRPI0815097A BRPI0815097A2 (pt) 2007-07-17 2008-07-16 agonistas de receptor acoplado à proteína g gpr119 de piridona
CN200880108168A CN101801957A (zh) 2007-07-17 2008-07-16 吡啶酮gpr119g蛋白偶联受体激动剂
DK08781867.0T DK2170864T3 (da) 2007-07-17 2008-07-16 Pyridon-GPR119-G-protein-koblede receptoragonister
PL08781867T PL2170864T3 (pl) 2007-07-17 2008-07-16 Agoniści receptora gpr119 sprężonego z białkiem g - pirydon
HR20110806T HRP20110806T1 (hr) 2007-07-17 2008-07-16 Agonisti piridon gpr119 g protein-vezanih receptora
AT08781867T ATE524460T1 (de) 2007-07-17 2008-07-16 Pyridon-gpr119-g-protein-gekoppelte rezeptoragonisten
EP08781867A EP2170864B1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists
HK10109487.9A HK1143136B (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists
AU2008276055A AU2008276055B2 (en) 2007-07-17 2008-07-16 Pyridone GPR119 G protein-coupled receptor agonists
EA201000210A EA018709B1 (ru) 2007-07-17 2008-07-16 Пиридоновые агонисты сопряженного с g-белком рецептора gpr119
CA2693439A CA2693439A1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists
JP2010517122A JP5318867B2 (ja) 2007-07-17 2008-07-16 ピリドンｇｐｒ１１９ｇタンパク質共役受容体アゴニスト
ZA2010/00151A ZA201000151B (en) 2007-07-17 2010-01-08 Pyridone gpr119 g protein-coupled receptor agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
US60/950,162 2007-07-17

Publications (2)

Publication Number Publication Date
WO2009012275A1 true WO2009012275A1 (en) 2009-01-22
WO2009012275A9 WO2009012275A9 (en) 2010-03-11

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/070101 Ceased WO2009012275A1 (en) 2007-07-17 2008-07-16 Pyridone gpr119 g protein-coupled receptor agonists
PCT/US2008/070103 Ceased WO2009012277A1 (en) 2007-07-17 2008-07-16 Method for modulating gpr119 g protein-coupled receptor and selected compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2008/070103 Ceased WO2009012277A1 (en) 2007-07-17 2008-07-16 Method for modulating gpr119 g protein-coupled receptor and selected compounds

Country Status (26)

Country Link
US (6) US7928230B2 (enExample)
EP (2) EP2170864B1 (enExample)
JP (3) JP5318867B2 (enExample)
KR (2) KR20100051814A (enExample)
CN (3) CN103550218A (enExample)
AR (2) AR067568A1 (enExample)
AT (2) ATE524460T1 (enExample)
AU (2) AU2008276057B2 (enExample)
BR (2) BRPI0814428A2 (enExample)
CA (2) CA2693444A1 (enExample)
CL (2) CL2008002111A1 (enExample)
CO (1) CO6160315A2 (enExample)
CY (2) CY1112151T1 (enExample)
DK (2) DK2173737T3 (enExample)
EA (2) EA016595B1 (enExample)
ES (2) ES2371515T3 (enExample)
HR (2) HRP20120221T1 (enExample)
IL (1) IL228120A0 (enExample)
NZ (2) NZ582661A (enExample)
PE (2) PE20090888A1 (enExample)
PL (2) PL2170864T3 (enExample)
PT (2) PT2173737E (enExample)
SI (2) SI2170864T1 (enExample)
TW (2) TW200904439A (enExample)
WO (2) WO2009012275A1 (enExample)
ZA (2) ZA201000151B (enExample)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009183A1 (en) * 2008-07-16 2010-01-21 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as gpr119 modulators
WO2010009195A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010009208A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
WO2010103335A1 (en) 2009-03-12 2010-09-16 Prosidion Limited Compounds for the treatment of metabolic disorders
WO2010106457A3 (en) * 2009-03-20 2010-11-18 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012046249A1 (en) 2010-10-08 2012-04-12 Cadila Healthcare Limited Novel gpr 119 agonists
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
WO2014202510A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
WO2014202505A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
WO2015004028A1 (de) 2013-07-08 2015-01-15 Bayer Cropscience Ag Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US9115089B2 (en) 2013-06-07 2015-08-25 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9365547B2 (en) 2010-12-06 2016-06-14 Confluence Life Sciences Inc. Substituted pyridinone-pyridinyl compounds
US9611277B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9611251B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted piperidine compounds and their use as orexin receptor modulators
US9611262B2 (en) 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9637496B2 (en) 2013-03-13 2017-05-02 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2021174048A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1820797A4 (en) * 2004-12-01 2009-10-28 Banyu Pharma Co Ltd SUBSTITUTED PYRIDONE DERIVATIVE
US7910583B2 (en) 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US7928230B2 (en) * 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP5935154B2 (ja) * 2011-03-14 2016-06-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｐｒ１１９モジュレーターとしてのｎ−シクロプロピル−ｎ−ピペリジニルベンズアミド
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
MY173812A (en) * 2012-11-13 2020-02-24 Nissan Chemical Ind Ltd 2-pyridone compound
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
US10399948B2 (en) 2015-02-10 2019-09-03 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
MX2022011755A (es) 2020-03-27 2022-11-16 Aclaris Therapeutics Inc Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos.
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
IL140622A0 (en) 1998-07-06 2002-02-10 Bristol Myers Squibb Co Biphenyl sufonamide derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
EP1058549A4 (en) 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
US6586418B2 (en) 2000-06-29 2003-07-01 Bristol-Myers Squibb Company Thrombin or factor Xa inhibitors
EP1770159A1 (en) 2000-12-01 2007-04-04 Astellas Pharma Inc. Process for manufacturing a pharmaceutical composition for treating diabetes
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
EP1465869B1 (en) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulators of lxr
PL218749B1 (pl) * 2002-02-14 2015-01-30 Pharmacia Corp Pochodna pirydynonu oraz jej zastosowanie do wytwarzania leku
HRP20050696B1 (en) 2003-01-14 2008-10-31 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
ES2316964T3 (es) 2003-02-24 2009-04-16 Arena Pharmaceuticals, Inc. Fenil-y piridilpipereidinia-derivados como moduladores del metabolismo de la glucosa.
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
CN100509798C (zh) * 2003-07-11 2009-07-08 艾尼纳制药公司 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症
WO2005025504A2 (en) 2003-09-12 2005-03-24 Kemia, Inc. Modulators of calcitonin and amylin activity
JPWO2005085200A1 (ja) * 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体
MXPA06010345A (es) 2004-03-17 2007-06-19 7Tm Pharma As Agonistas de receptor selectivo de y4 para intervenciones terapeuticas.
ES2329489T3 (es) 2004-05-03 2009-11-26 F. Hoffmann-La Roche Ag Derivados de indolilo como moduladores del receptor x del higado.
UA92150C2 (ru) 2004-06-04 2010-10-11 Арена Фармасьютикалз, Инк. Замещенные производные арила и гетероарила как модуляторы метаболизма и для профилактики и лечения связанных с ним расстройств
US8193359B2 (en) 2004-12-24 2012-06-05 Prosidion Limited G-protein coupled receptor agonists
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007001958A2 (en) 2005-06-23 2007-01-04 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
JP5114395B2 (ja) * 2005-06-30 2013-01-09 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
JP2010526146A (ja) * 2007-05-04 2010-07-29 ブリストル−マイヤーズ スクイブ カンパニー ［６，５］−二環式ｇｐｒ１１９ｇタンパク質結合受容体アゴニスト
US7910583B2 (en) * 2007-05-04 2011-03-22 Bristol-Myers Squibb Company [6,6] and [6,7]-bicyclic GPR119 G protein-coupled receptor agonists
US7928230B2 (en) 2007-07-17 2011-04-19 Bristol-Myers Squibb Company Method for modulating GPR119 G protein-coupled receptor and selected compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007647A1 (en) * 2003-07-11 2005-01-27 Arena Pharmaceuticals, Inc. Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2005007658A2 (en) * 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto

Cited By (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9290450B2 (en) 2008-06-03 2016-03-22 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8969347B2 (en) 2008-06-03 2015-03-03 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8822480B2 (en) 2008-07-16 2014-09-02 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
WO2010009195A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
WO2010009208A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
CN102159566A (zh) * 2008-07-16 2011-08-17 百时美施贵宝公司 作为gpr119调节剂的吡啶酮和哒嗪酮类似物
EA018268B1 (ru) * 2008-07-16 2013-06-28 Бристол-Маерс Сквибб Компани Аналоги пиридона и пиридазона как модуляторы gpr119
US8815876B2 (en) 2008-07-16 2014-08-26 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
WO2010009183A1 (en) * 2008-07-16 2010-01-21 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as gpr119 modulators
US8372837B2 (en) 2008-07-16 2013-02-12 Bristol-Myers Squibb Company Pyridone and pyridazone analogues as GPR119 modulators
WO2010103335A1 (en) 2009-03-12 2010-09-16 Prosidion Limited Compounds for the treatment of metabolic disorders
WO2010106457A3 (en) * 2009-03-20 2010-11-18 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011113947A1 (en) 2010-03-18 2011-09-22 Boehringer Ingelheim International Gmbh Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
CN102933576A (zh) * 2010-04-08 2013-02-13 百时美施贵宝公司 作为gpr119调节剂的嘧啶基哌啶基氧基吡啶酮类似物
US20110251221A1 (en) * 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
WO2011127106A1 (en) 2010-04-08 2011-10-13 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as gpr119 modulators
US8415367B2 (en) 2010-04-08 2013-04-09 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridinone analogues as GPR119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011161030A1 (de) 2010-06-21 2011-12-29 Sanofi Heterocyclisch substituierte methoxyphenylderivate mit oxogruppe, verfahren zu ihrer herstellung und ihre verwendung als gpr40 rezeptor modulatoren
WO2012004270A1 (de) 2010-07-05 2012-01-12 Sanofi Spirocyclisch substituierte 1,3-propandioxidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012010413A1 (de) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylen-substituierte hydroxy-phenyl-hexinsäuren, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012004269A1 (de) 2010-07-05 2012-01-12 Sanofi ( 2 -aryloxy -acetylamino) - phenyl - propionsäurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2012046249A1 (en) 2010-10-08 2012-04-12 Cadila Healthcare Limited Novel gpr 119 agonists
US9365547B2 (en) 2010-12-06 2016-06-14 Confluence Life Sciences Inc. Substituted pyridinone-pyridinyl compounds
US9365546B2 (en) 2010-12-06 2016-06-14 Confluence Life Sciences Inc. Substituted pyridinone-pyridinyl compounds
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9174965B2 (en) 2012-05-16 2015-11-03 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators
WO2014011926A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
EA034171B1 (ru) * 2012-10-02 2020-01-14 Интермьюн, Инк. Противофиброзные пиридиноны
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
JP2018135356A (ja) * 2012-10-02 2018-08-30 インターミューン， インコーポレイテッド 抗線維性ピリジノン
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US9637496B2 (en) 2013-03-13 2017-05-02 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
US10183953B2 (en) 2013-03-13 2019-01-22 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9611251B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted piperidine compounds and their use as orexin receptor modulators
US9695183B2 (en) 2013-03-13 2017-07-04 Janssen Pharmaceutica Nv Substituted 7-azabicycles and their use as orexin receptor modulators
US9845333B2 (en) 2013-03-13 2017-12-19 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9611277B2 (en) 2013-03-13 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
US9636333B2 (en) 2013-06-07 2017-05-02 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US9115089B2 (en) 2013-06-07 2015-08-25 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
WO2014202510A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
WO2014202505A1 (de) 2013-06-20 2014-12-24 Bayer Cropscience Ag Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
WO2015004028A1 (de) 2013-07-08 2015-01-15 Bayer Cropscience Ag Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US9611262B2 (en) 2014-09-11 2017-04-04 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2021174048A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
US12264171B2 (en) 2020-02-28 2025-04-01 Kallyope, Inc. GPR40 agonists
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Also Published As

Publication number Publication date
ES2371515T3 (es) 2012-01-04
CN101801957A (zh) 2010-08-11
EP2170864B1 (en) 2011-09-14
JP5301539B2 (ja) 2013-09-25
CO6160315A2 (es) 2010-05-20
US8178561B2 (en) 2012-05-15
US20110190327A1 (en) 2011-08-04
TW200904440A (en) 2009-02-01
ATE524460T1 (de) 2011-09-15
PL2170864T3 (pl) 2012-02-29
CN103550218A (zh) 2014-02-05
JP5318867B2 (ja) 2013-10-16
AR067568A1 (es) 2009-10-14
NZ582661A (en) 2012-03-30
AU2008276057A1 (en) 2009-01-22
US20120232048A1 (en) 2012-09-13
US20120258959A1 (en) 2012-10-11
SI2170864T1 (sl) 2012-04-30
US20090042919A1 (en) 2009-02-12
AU2008276055B2 (en) 2013-01-31
EA016595B1 (ru) 2012-06-29
JP2010533726A (ja) 2010-10-28
BRPI0814428A2 (pt) 2015-01-06
SI2173737T1 (sl) 2012-05-31
JP2010533727A (ja) 2010-10-28
US7928230B2 (en) 2011-04-19
CA2693444A1 (en) 2009-01-22
EA018709B1 (ru) 2013-10-30
HK1136298A1 (en) 2010-06-25
KR20100051814A (ko) 2010-05-18
AU2008276057B2 (en) 2013-01-31
DK2173737T3 (da) 2012-05-07
US8513424B2 (en) 2013-08-20
PL2173737T3 (pl) 2012-06-29
BRPI0815097A2 (pt) 2018-07-24
KR20100045471A (ko) 2010-05-03
WO2009012277A1 (en) 2009-01-22
PE20090888A1 (es) 2009-07-15
EA201000211A1 (ru) 2010-06-30
CA2693439A1 (en) 2009-01-22
EP2173737B1 (en) 2012-01-11
HRP20120221T1 (hr) 2012-04-30
ES2378914T3 (es) 2012-04-19
US8003796B2 (en) 2011-08-23
CL2008002110A1 (es) 2008-10-24
PE20090449A1 (es) 2009-04-18
HRP20110806T1 (hr) 2011-11-30
US20110245227A1 (en) 2011-10-06
US20090023702A1 (en) 2009-01-22
TW200904439A (en) 2009-02-01
EA201000210A1 (ru) 2010-06-30
CL2008002111A1 (es) 2008-10-24
WO2009012275A9 (en) 2010-03-11
CY1112151T1 (el) 2015-12-09
ATE540945T1 (de) 2012-01-15
PT2173737E (pt) 2012-03-19
EP2170864A1 (en) 2010-04-07
CN101801956A (zh) 2010-08-11
JP2013237680A (ja) 2013-11-28
EP2173737A1 (en) 2010-04-14
IL228120A0 (en) 2013-09-30
DK2170864T3 (da) 2012-01-16
CY1112751T1 (el) 2016-02-10
NZ582664A (en) 2012-03-30
ZA201000326B (en) 2011-03-30
AR067569A1 (es) 2009-10-14
HK1143136A1 (en) 2010-12-24
AU2008276055A1 (en) 2009-01-22
PT2170864E (pt) 2011-11-25
CN101801956B (zh) 2013-11-20
US8232404B2 (en) 2012-07-31
ZA201000151B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
AU2008276055B2 (en) Pyridone GPR119 G protein-coupled receptor agonists
EP2313395B1 (en) Pyridone and pyridazone analogues as gpr119 modulators
EP2566860B1 (en) Bicyclic heteroaryl compounds as gpr119 modulators
HK1143136B (en) Pyridone gpr119 g protein-coupled receptor agonists
HK1136298B (en) Method for modulating gpr119 g protein-coupled receptor and selected compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880108168.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781867

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/000498

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 582664

Country of ref document: NZ

Ref document number: 2693439

Country of ref document: CA

Ref document number: 10003756

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 203349

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2010517122

Country of ref document: JP

Ref document number: 2008276055

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 415/DELNP/2010

Country of ref document: IN

Ref document number: 2008781867

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008276055

Country of ref document: AU

Date of ref document: 20080716

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201000210

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 20107003332

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0815097

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100118